Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection

(2020) Amandine Landemaine et al.   Clinical Gastroenterology and Hepatology

Infliximab levels and antibodies in IBD-related peripheral arthralgia

(2020) Asaf Levartovsky et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring

(2019) Amit Assa et al.   GASTROENTEROLOGY

How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

(2019) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease

(2018) Tomer Greener et al.   INFLAMMATORY BOWEL DISEASES

Success and safety of high infliximab trough levels in inflammatory bowel disease

(2018) David Drobne et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

(2015) Isabelle Cleynen et al.   ANNALS OF INTERNAL MEDICINE